Project Grant R01HL177519
Award Date 9/15/25
Completion Date 6/30/29
Dollars Obligated $787K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This Project Grant award, valued at $167,400.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will support research by Brigham & Women's Hospital Inc. to investigate how the immune mediator CD70 regulates endothelial metabolism and function, with the goal of identifying novel therapeutic targets for atherosclerotic cardiovascular disease. The 5-year project will comprehensively examine the role of CD70 in impairing endothelial...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- This $800,962 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Brigham & Women's Hospital on the molecular mechanisms regulating fibroproliferative pulmonary vasculopathy in early pulmonary arterial hypertension (PAH). The research aims to investigate the role of the c-terminal Src kinase (CSK) and its regulation of Src kinase activation in the context of endothelial dysfunction and fibrosis,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $834,531 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct research on the effects of IL-1 beta inhibition on vascular inflammation in individuals with clonal hematopoiesis of indeterminate potential (CHIP), a risk factor for atherosclerotic cardiovascular disease. The research aims to investigate vascular...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $692,742 to support research on the role of a novel hormone complex called FABKIN in regulating dyslipidemia and inflammation that contribute to atherosclerosis. The award was made to the President and Fellows of Harvard College, specifically the Harvard T.H. Chan School of Public Health, and runs from September 2025 to May 2029. The research aims to...
- This $548,816 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Illinois to investigate the role of the SEC16B protein in regulating lipid metabolism and transport in the liver. The project aims to define how SEC16B mediates the formation of lipid droplets and very low-density lipoprotein (VLDL) secretion, which are key processes involved in cholesterol and triglyceride homeostasis. This...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- The University of Texas Southwestern Medical Center received a $772,275 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on how endothelial cell scavenger receptor class B type I (SR-BI) is regulated and interacts with other proteins to drive LDL transcytosis and promote atherosclerosis. The award, effective August 25, 2025 through May 31, 2029, aims to determine the mechanisms by which hypercholesterolemia and...
- This Project Grant award of $786,188, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy platform to prevent the failure of prosthetic bypass grafts used to treat arterial blockages in the lower extremities. The research, conducted by Beth Israel Deaconess Medical Center, Inc. (BIDMC), focuses on optimizing a biodegradable hydrogel system that can deliver small interfering RNA...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Inc.) to assess the impact of improving cardiovascular disease (CVD) care for adults with diagnosed diabetes across diverse global settings. The project, led by Dr. Jennifer Manne-Goehler and an interdisciplinary team, aims to develop the PREDICT-DM global...